In this narrative review, we summarize the literature on axSpA and PsA, examining the physiological link between the inflammatory state and cardiometabolic comorbidities, as well as the impact and efficacy of IL-17–targeted therapy in spondyloarthritis patients with cardiometabolic comorbidities. This evidence concerns the gene IL17A and spondyloarthropathy.